Zevra Therapeutics (ZVRA) Assets (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Assets came in at $278.6 million in Q1 2026, up 61.3% YoY from $172.7 million in Q1 2025, and down 2.16% on a QoQ basis from $284.7 million in Q4 2025.
Zevra Therapeutics (ZVRA) Assets (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Assets data on file, last reported at $278.6 million in Q1 2026.
- Quarterly Assets rose 61.3% year-over-year to $278.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $278.6 million (up 61.3% YoY) and the FY2025 annual result came in at $284.7 million, up 59.85% from the prior year.
- Assets declined to $278.6 million in Q1 2026, from $284.7 million in the prior quarter.
- In the past five years, Assets ranged from a high of $284.7 million in Q4 2025 to a low of -$426000.0 in Q1 2022.
- A 5-year average of $168.9 million and a median of $161.8 million in 2023 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets tumbled 100.47% — and 2025, when it soared 77.47%.
- Tracing ZVRA's Assets over 5 years: stood at $115.3 million in 2022, then surged by 49.41% to $172.3 million in 2023, then climbed by 3.37% to $178.1 million in 2024, then jumped by 59.85% to $284.7 million in 2025, then declined by 2.16% to $278.6 million in 2026.
- The last three Assets figures came in at $278.6 million (Q1 2026), $284.7 million (Q4 2025), and $270.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 302.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 302.71 Mn |
| Mar 31, 2026 | 278.58 Mn |
| Dec 31, 2025 | 284.73 Mn |
| Sep 30, 2025 | 270.12 Mn |
| Jun 30, 2025 | 256.28 Mn |
| Mar 31, 2025 | 172.71 Mn |
| Dec 31, 2024 | 178.13 Mn |
| Sep 30, 2024 | 191.55 Mn |
| Jun 30, 2024 | 144.41 Mn |
| Mar 31, 2024 | 151.28 Mn |
| Dec 31, 2023 | 172.33 Mn |
| Sep 30, 2023 | 138.98 Mn |
| Jun 30, 2023 | 105.52 Mn |
| Dec 31, 2022 | 115.34 Mn |
| Sep 30, 2022 | 119.13 Mn |
| Jun 30, 2022 | 124.26 Mn |
| Mar 31, 2022 | -426,000.00 |
| Dec 31, 2021 | 132.94 Mn |
| Sep 30, 2021 | 137.19 Mn |
| Jun 30, 2021 | 138.80 Mn |